Company Overview
- Website
- dantari.com
- Phone
- (805) 490-9704
- Employees
- 9
- Industry
- BioTech/Drugs
- SIC Code
-
8731 - Commercial Physical and Biological Research
Financials & Stats
Revenue
$10B
Recent News & Media
Abstract PO3-18-12: Results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi [NCT05261269]
- May 2, 2024
- aacrjournals.org
Dantari's Novel High-Capacity Drug Conjugate DAN-222 Shows Promising Antitumor Activity in Patients with Metastatic HER2-Negative Breast Cancer
- Dec 7, 2023
- prnewswire.com
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
- Dec 6, 2023
- ascopost.com
Abstract OT3-28-01: A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects with Metastatic Breast Cancer NCT05261269
- Mar 1, 2023
- aacrjournals.org
Dantari Debuts with $47M to Make Better ADCs
- Dec 8, 2022
- biospace.com
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
- Dec 8, 2022
- biospace.com
Companies Similar to Dantari Inc
Analyze industry trends and opportunities by examining competitors and companies comparable to Dantari Inc, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 10M | 59 | Boston, MA | ||
| 10M | 27 | Cambridge, MA | 2010 | |
| 10M | 23 | Waltham, MA | 1999 | |
| 10M | 2 | Boston, MA | ||
| 10M | 46 | Woburn, MA |